KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.

Ciara C O'Sullivan, Karla V Ballman, Linda McCall, Anuhya Kommalapati, Tyler Zemla, Anna Weiss, Melissa Mitchell, Victoria Blinder, Nadine M Tung, William J Irvin, Myounghee Lee, Matthew P Goetz, William Fraser Symmans, Virginia F Borges, Ian Krop, Lisa A Carey, Ann H Partridge

Future Oncol 17(34) 4665-4676

PMID34636255
PMCIDPMC8600597
DOI10.2217/fon-2021-0753
发表日期2021-10-12
摘要

摘要

This report describes the rationale, purpose and design of A011801 (CompassHER2 RD), an ongoing prospective, multicenter, Phase III randomized trial. Eligible patients in the United States (US) and Canada with high-risk (defined as ER-negative and/or node-positive) HER2-positive (HER2+) residual disease (RD) after a predefined course of neoadjuvant chemotherapy and HER2-directed treatment are randomized 1:1 to adjuvant T-DM1 and placebo, versus T-DM1 and tucatinib. Patients have also received adjuvant radiotherapy and/or endocrine therapy, if indicated per standard of care guidelines. The primary objective of the trial is to determine if the invasive disease-free survival (iDFS) with T-DM1 plus tucatinib is superior to iDFS with T-DM1 plus placebo; other outcomes of interest include overall survival (OS), breast cancer-free survival (BCFS), distant recurrence-free survival (DRFS), brain metastases-free survival (BMFS) and disease-free survival (DFS). Correlative biomarker, quality of life (QoL) and pharmacokinetic (PK) end points are also evaluated.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。